iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
ETFs & Funds · EUR · XETRA
Price
€7.459
Cap
—
Earnings
—
30d Trend
+2.5%
20% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 68×Macro 0.99 (−1%)=67
RISK
MOMENTUM
TECHNICAL
FUND QUALITY
COST EFFICIENCY
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Long-term compounder — quality business with growth runway
BRAIN47'S ASSESSMENT
I rate iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) at 67/100 — a STRONG reading on the Brain47 Signal. The strongest factor is risk management at 75/100. I classify this as a growth position with the strongest thesis on a long-term horizon.
PAST PERFORMANCE
1 MONTH
+2.6%
3 MONTHS
+0.4%
12 MONTHS
+41.0%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Long-term compounder — quality business with growth runway. low-risk profile and Fund Quality (75) are the primary strengths. Historical volatility is normal at 20%. I classify this as a growth position — strong momentum combined with solid fundamentals points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.